Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
12:27a BEWHERE HOLDINGS INC. : Over Subscribed Non-Brokered Private Placement
12:21a KROGER : Pay Less store at Cross Street expanding
12:21a ASSOCIATED CAPITAL : Gabelli Go Anywhere Trust - 15th Gabelli Closed-End Fund
12:19a WOOD RESOURCES INTERNATIONAL LLC : North American Log and Lumber Exports to Asia Fell by 33% from 2013 to 2015, with the 2016 Exports on Pace to Reach the Lowest Level since 2010
12:18a NZX MARKET ANNOUNCEMENT : Allotment of Shares
12:18a BENITEC BIOPHARMA : Quarterly report conference call transcript
12:18a Fitch Rates Third Funding Date Notes Issued by Guggenheim Private Debt Fund Note Issuer 2.0, LLC
12:17a K12 : Blended Learning Prepares Students for Success in 2016-2017 School Year
12:16a ECOBALT SOLUTIONS INC. : Reports Annual Meeting Voting Results
12:16a ECOBALT : Reports Annual Meeting Voting Results
Latest news
Advertisement
Hot News 
-20.31%ABERCROMBIE & FITCH : no longer sees comparable sales improving this year
-10.76%Mondelez abandons pursuit of U.S. chocolate maker Hershey
-20.66%G III APPAREL : III Cuts Earnins View Amid Surprise Loss
-10.34%DSW : Affirms Outlook After Completing Review
3.95%Mondelez Drops Offer For Hershey -- WSJ
Most Read News
06:08p K12 : Back to School for Insight School of Washington Students Means Powering Up the Computer
06:18p BENITEC BIOPHARMA : Quarterly report conference call transcript
06:04p DUKE ENERGY : solar developers sign agreement on grid connections
06:12p DUNDEE CORPORATION : and United Hydrocarbon International Corp. Announce Restructuring
06:03p LABOUR LEADERSHIP ELECTION : Corbyn leads Smith by 24 points
Most recommended articles
05:59p U.S. slams EU, but Apple tax demand first issued in Washington
05:55pDJConsortium Submits Bid to Save 229 Aé ropostale Stores
05:53p Prosecutors to decide in September on Samarco dam spill charges
05:46pDJCHEVRON : U.S. Oil Firms Continue Tussle Over Taxes -- Update
05:37pDJAnalysts Forecast 1.2 Million-Barrel Increase in Crude Stocks